Research and Clinical Trials
At any given time, approximately 500 clinical trials are occurring at Greenville Health System (GHS) in the areas of oncology, pediatric oncology, women’s health, cardiology and vascular disease. Clinical trials are structured research studies conducted to answer specific questions concerning new therapies, medications, medical devices, vaccines, or new ways of using existing treatment. Trials are sponsored or funded by a variety of organizations from federal agencies to physicians, medical institutions, foundations, and pharmaceutical or medical device companies. This innovative research often results in medical breakthroughs and gives our patients access to the latest treatments, therapies, and medications.
In addition to clinical research, GHS also participates in applied basic science to support the development of new medical devices and drug therapies in the areas of oncology, reproductive endocrinology and vascular surgery.
CONTACT FOR QUESTIONS (PARTICIPANTS)
The consent form that you receive when you are invited to be a research subject includes some contact information if you have questions or concerns about the study.
For more information concerning research study(s) and research-related risks or injuries, or to give comments, concerns or complaints, you may contact a representative of the Institutional Review Board of the Greenville Health System for information regarding your rights as a participant involved in a research. You may obtain the name and number of this person by calling (864) 455-8997.
A survey about your experience with this informed consent process is located at the following website: https://www.surveymonkey.com/s/T5C86P8
Participation in the survey is completely anonymous and voluntary and will not affect your relationship with your doctor or the GHS.
If you would like to have a paper copy of this survey, please tell your study doctor.
The Office of Human Research Protection
The Office of Human Research Protection is the support structure for the Institutional Review Board (IRB). The office works with investigators to protect the rights and welfare of research participants. Staff pre-reviews submissions to the Institutional Review Board, providing feedback, consultation, and interpretation of applicable regulations.
The Institutional Review Board supervises a varied, high-volume body of research, ranging from pioneering therapies to chart reviews. IRB-supervised research helps to attract and retain a wide range of specialists who offer the latest expertise in patient care.
IRBs are responsible for ensuring that patients’ rights and safety are protected throughout the process. Everything from the language in a consent form to the dosage and administration of new drugs is scrutinized. An IRB committee is made up of physicians, nurses, pharmacists, clergy, and community members who volunteer their time to review proposals for new research and to review existing clinical trials. At GHS, there are three IRB committees.
- IRB Committee A – Reviews all types of research except oncology
- IRB Committee B – Reviews all pediatric research, as well as additional research, as needed (except adult oncology)
- IRB Committee C – Reviews adult oncology research
Christopher Wright, MD
Medical Director, GHS OHRP
(864) 455-8997 Telefax: (864) 455-6766
Sharon Davis, Coordinator, IRB-Committee C
(864) 455-6607 Telefax: (864) 455-6766
Glyn Hamilton, Coordinator, IRB-Committee B
(864) 455-4360 Telefax: (864) 455-6766
Kelly Stephens, Coordinator, IRB-Committee A
(864) 455-4984 Telefax: (864) 455-6766
Jean Winter, eIRB Coordinator
(864) 455-3145 Telefax: (864) 455-6766